NVSEF
Novartis AG
Price Chart
Latest Quote
$145.00
+0.00 (+0.00%)
Current Price
| Previous Close | $145.00 |
| Open | $148.80 |
| Day High | $148.80 |
| Day Low | $148.80 |
| Volume | 800 |
Stock Information
| Quarterly Dividend / Yield | $4.73 / 3.26% |
| Shares Outstanding | 1.91B |
| Quarterly Dividend Yield | 3.26% |
| Quarterly Dividend | $4.73 |
| Total Debt | $47.00B |
| Cash Equivalents | $6.89B |
| Revenue | $56.58B |
| Net Income | $13.53B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $276.67B |
| P/E Ratio | 20.80 |
| EPS (TTM) | $6.97 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $317.19B |
| Sales | $56.58B |
| Income | $13.53B |
| Book/sh | $20.18 |
| Cash/sh | $3.61 |
| Employees | 75K |
Financial Ratios
| Quick Ratio | 0.53 |
| Current Ratio | 0.85 |
| Debt/Eq | 120.73 |
| EPS Growth TTM | -12.50% |
Returns & Margins
| ROA | 10.54% |
| ROE | 34.93% |
| Gross Margin | 75.55% |
| Operating Margin | 30.48% |
| Profit Margin | 23.92% |
Ownership
| Insider Ownership | 2.11% |
| Institutional Ownership | 45.98% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 3.93 |
| P/S | 4.89 |
| P/B | 7.18 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $145.80 |
| SMA50 | $146.22 |
| SMA200 | $140.90 |
| RSI | 54.25 |
| ATR | 1.0093 |
| Shares Float | 1.81B |
| Volatility | 0.49 |
Performance History
| Week | +0.08% |
| Month | +1.65% |
| Quarter | -3.46% |
| 6 Months | +4.47% |
| YTD | +5.07% |
| Year | +21.66% |
| 3 Years | +62.93% |
| 5 Years | +92.65% |
| 10 Years | +171.25% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $145.00 | 0 |
| 2026-06-17 | $145.00 | 1,200 |
| 2026-06-16 | $147.07 | 7,600 |
| 2026-06-15 | $144.88 | 0 |
| 2026-06-12 | $144.88 | 0 |
| 2026-06-11 | $144.88 | 0 |
| 2026-06-10 | $144.88 | 0 |
| 2026-06-09 | $144.88 | 0 |
| 2026-06-08 | $144.88 | 0 |
| 2026-06-05 | $144.88 | 1,045,600 |
| 2026-06-04 | $143.88 | 800 |
| 2026-06-03 | $144.14 | 0 |
| 2026-06-02 | $144.14 | 100,100 |
| 2026-06-01 | $144.50 | 0 |
| 2026-05-29 | $144.50 | 80,000 |
| 2026-05-28 | $146.84 | 1,000 |
| 2026-05-27 | $151.00 | 0 |
| 2026-05-26 | $151.00 | 1,800 |
| 2026-05-22 | $145.78 | 300 |
| 2026-05-21 | $149.06 | 1,800 |
| 2026-05-20 | $142.65 | 0 |
| 2026-05-19 | $142.65 | 0 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
đ° Latest News
Swiss voters likely to reject stricter neutrality proposal, poll shows
Investing.com âĸ 2026-06-21T05:21:30ZASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain
Pharmaceutical Technology âĸ 2026-06-19T09:13:51Z
Switzerland Voted Against a Population Cap but This Isnât the Last Weâll Hear About It
Barrons.com âĸ 2026-06-19T07:00:00Z
This Biotech Stock Is Surging 81% on Surprise Good News From FDA
Barrons.com âĸ 2026-06-17T19:33:00Z
Vedana debuts with $46m to progress migraine therapies
Pharmaceutical Technology âĸ 2026-06-17T16:39:52Z
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
Zacks âĸ 2026-06-16T16:53:00Z
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
Zacks âĸ 2026-06-15T14:30:00Z
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
Simply Wall St. âĸ 2026-06-14T10:09:16Z
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Zacks âĸ 2026-06-11T17:24:00Z
Novartis Reports Positive Data for Neuromuscular Disorder Drug
Zacks âĸ 2026-06-11T17:23:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $12,827,000,000 | $12,472,000,000 | $11,582,000,000 | $11,735,000,000 |
| Cost Of Revenue | $12,827,000,000 | $12,472,000,000 | $11,582,000,000 | $11,735,000,000 |
| Total Revenue | $51,722,000,000 | $46,660,000,000 | $43,461,000,000 | $43,974,000,000 |
| Operating Revenue | $50,317,000,000 | $45,440,000,000 | $42,206,000,000 | $42,781,000,000 |
| Expenses | ||||
| Interest Expense | $1,006,000,000 | $855,000,000 | $800,000,000 | $787,000,000 |
| Total Expenses | $37,178,000,000 | $36,891,000,000 | $35,515,000,000 | $33,918,000,000 |
| Other Income Expense | $-218,000,000 | $-227,000,000 | $-195,000,000 | $15,268,000,000 |
| Net Non Operating Interest Income Expense | $-686,000,000 | $-419,000,000 | $-574,000,000 | $-794,000,000 |
| Total Other Finance Cost | $248,000,000 | $191,000,000 | $151,000,000 | $77,000,000 |
| Interest Expense Non Operating | $1,006,000,000 | $855,000,000 | $800,000,000 | $787,000,000 |
| Operating Expense | $24,351,000,000 | $24,419,000,000 | $23,933,000,000 | $22,183,000,000 |
| Other Operating Expenses | $1,763,000,000 | $531,000,000 | $2,568,000,000 | $715,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $11,941,000,000 | $8,568,000,000 | $6,049,000,000 | $22,908,000,000 |
| Net Interest Income | $-686,000,000 | $-419,000,000 | $-574,000,000 | $-794,000,000 |
| Interest Income | $568,000,000 | $627,000,000 | $377,000,000 | $70,000,000 |
| Normalized Income | $12,098,500,000 | $8,769,160,000 | $6,204,112,000 | $22,971,411,000 |
| Net Income From Continuing And Discontinued Operation | $11,941,000,000 | $14,850,000,000 | $6,955,000,000 | $24,021,000,000 |
| Total Operating Income As Reported | $14,544,000,000 | $9,769,000,000 | $7,946,000,000 | $10,056,000,000 |
| Net Income Common Stockholders | $11,941,000,000 | $14,850,000,000 | $6,955,000,000 | $24,021,000,000 |
| Net Income | $11,941,000,000 | $14,850,000,000 | $6,955,000,000 | $24,021,000,000 |
| Net Income Including Noncontrolling Interests | $11,939,000,000 | $14,854,000,000 | $6,955,000,000 | $24,018,000,000 |
| Net Income Continuous Operations | $11,939,000,000 | $8,572,000,000 | $6,049,000,000 | $22,905,000,000 |
| Pretax Income | $13,640,000,000 | $9,123,000,000 | $7,177,000,000 | $24,530,000,000 |
| Earnings From Equity Interest | $-38,000,000 | $-13,000,000 | $-11,000,000 | $15,337,000,000 |
| Interest Income Non Operating | $568,000,000 | $627,000,000 | $377,000,000 | $70,000,000 |
| Operating Income | $14,544,000,000 | $9,769,000,000 | $7,946,000,000 | $10,056,000,000 |
| Gross Profit | $38,895,000,000 | $34,188,000,000 | $31,879,000,000 | $32,239,000,000 |
| Net Income Discontinuous Operations | - | $6,282,000,000 | $906,000,000 | $1,113,000,000 |
| Per Share | ||||
| Diluted EPS | $5.87 | $7.10 | $3.17 | $10.63 |
| Basic EPS | $5.92 | $7.15 | $3.19 | $10.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $-22,500,000 | $-12,840,000 | $-28,888,000 | $-5,589,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $20,895,000,000 | $18,469,000,000 | $14,866,000,000 | $30,983,000,000 |
| Total Unusual Items | $-180,000,000 | $-214,000,000 | $-184,000,000 | $-69,000,000 |
| Total Unusual Items Excluding Goodwill | $-180,000,000 | $-214,000,000 | $-184,000,000 | $-69,000,000 |
| Reconciled Depreciation | $6,069,000,000 | $8,277,000,000 | $6,705,000,000 | $5,597,000,000 |
| EBITDA (Bullshit earnings) | $20,715,000,000 | $18,255,000,000 | $14,682,000,000 | $30,914,000,000 |
| EBIT | $14,646,000,000 | $9,978,000,000 | $7,977,000,000 | $25,317,000,000 |
| Diluted Average Shares | $2,035,000,000 | $2,092,000,000 | $2,197,000,000 | $2,260,000,000 |
| Basic Average Shares | $2,018,000,000 | $2,077,000,000 | $2,181,000,000 | $2,243,000,000 |
| Diluted NI Availto Com Stockholders | $11,941,000,000 | $14,850,000,000 | $6,955,000,000 | $24,021,000,000 |
| Minority Interests | $2,000,000 | $-4,000,000 | $0 | $3,000,000 |
| Tax Provision | $1,701,000,000 | $551,000,000 | $1,128,000,000 | $1,625,000,000 |
| Gain On Sale Of Security | $-180,000,000 | $-214,000,000 | $-184,000,000 | $-69,000,000 |
| Research And Development | $10,022,000,000 | $11,371,000,000 | $9,172,000,000 | $8,641,000,000 |
| Selling General And Administration | $12,566,000,000 | $12,517,000,000 | $12,193,000,000 | $12,827,000,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-7,625,000,000 | $-3,553,000,000 | $-1,603,000,000 | $3,878,000,000 |
| Total Assets | $102,246,000,000 | $99,945,000,000 | $117,453,000,000 | $131,795,000,000 |
| Total Non Current Assets | $72,542,000,000 | $69,464,000,000 | $80,543,000,000 | $86,077,000,000 |
| Other Non Current Assets | $422,000,000 | $215,000,000 | $200,000,000 | $275,000,000 |
| Non Current Deferred Assets | $4,838,000,000 | $4,748,000,000 | $4,158,000,000 | $4,263,000,000 |
| Non Current Deferred Taxes Assets | $4,359,000,000 | $4,309,000,000 | $3,739,000,000 | $3,743,000,000 |
| Non Current Note Receivables | $102,000,000 | $114,000,000 | $85,000,000 | $78,000,000 |
| Non Current Accounts Receivable | $904,000,000 | $871,000,000 | $863,000,000 | $895,000,000 |
| Investmentin Financial Assets | $1,009,000,000 | $1,622,000,000 | $1,463,000,000 | $2,063,000,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $518,000,000 | $507,000,000 | $598,000,000 | $834,000,000 |
| Goodwill And Other Intangible Assets | $51,671,000,000 | $50,220,000,000 | $60,945,000,000 | $63,777,000,000 |
| Other Intangible Assets | $26,915,000,000 | $26,879,000,000 | $31,644,000,000 | $34,182,000,000 |
| Current Assets | $29,704,000,000 | $30,481,000,000 | $36,910,000,000 | $45,718,000,000 |
| Hedging Assets Current | $106,000,000 | $466,000,000 | $315,000,000 | $216,000,000 |
| Prepaid Assets | $985,000,000 | $764,000,000 | $911,000,000 | $1,102,000,000 |
| Inventory | $5,723,000,000 | $5,913,000,000 | $7,175,000,000 | $6,666,000,000 |
| Receivables | $9,539,000,000 | $9,376,000,000 | $9,894,000,000 | $9,621,000,000 |
| Other Receivables | $1,448,000,000 | $1,317,000,000 | $1,001,000,000 | $793,000,000 |
| Taxes Receivable | $668,000,000 | $952,000,000 | $827,000,000 | $823,000,000 |
| Accounts Receivable | $7,423,000,000 | $7,107,000,000 | $8,066,000,000 | $8,005,000,000 |
| Allowance For Doubtful Accounts Receivable | $-58,000,000 | $-51,000,000 | $-62,000,000 | $-83,000,000 |
| Gross Accounts Receivable | $7,481,000,000 | $7,158,000,000 | $8,128,000,000 | $8,088,000,000 |
| Cash Cash Equivalents And Short Term Investments | $13,351,000,000 | $13,962,000,000 | $18,615,000,000 | $28,113,000,000 |
| Cash And Cash Equivalents | $11,459,000,000 | $13,393,000,000 | $7,517,000,000 | $12,407,000,000 |
| Cash Equivalents | $8,874,000,000 | $10,186,000,000 | $4,640,000,000 | $9,011,000,000 |
| Cash Financial | $2,585,000,000 | $3,207,000,000 | $2,877,000,000 | $3,396,000,000 |
| Other Current Assets | - | - | $2,739,000,000 | $2,718,000,000 |
| Debt | ||||
| Net Debt | $17,996,000,000 | $11,127,000,000 | $18,603,000,000 | $16,722,000,000 |
| Total Debt | $31,258,000,000 | $26,348,000,000 | $27,909,000,000 | $31,025,000,000 |
| Long Term Debt And Capital Lease Obligation | $22,934,000,000 | $20,034,000,000 | $21,782,000,000 | $24,523,000,000 |
| Long Term Debt | $21,366,000,000 | $18,436,000,000 | $20,244,000,000 | $22,902,000,000 |
| Current Debt And Capital Lease Obligation | $8,324,000,000 | $6,314,000,000 | $6,127,000,000 | $6,502,000,000 |
| Current Debt | $8,089,000,000 | $6,084,000,000 | $5,876,000,000 | $6,227,000,000 |
| Other Current Borrowings | $3,356,000,000 | $2,191,000,000 | $2,241,000,000 | $4,435,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $58,120,000,000 | $53,195,000,000 | $58,030,000,000 | $63,973,000,000 |
| Total Non Current Liabilities Net Minority Interest | $29,428,000,000 | $26,805,000,000 | $29,374,000,000 | $33,765,000,000 |
| Other Non Current Liabilities | $1,041,000,000 | $1,193,000,000 | $1,578,000,000 | $1,475,000,000 |
| Non Current Deferred Liabilities | $2,419,000,000 | $2,248,000,000 | $2,686,000,000 | $3,070,000,000 |
| Non Current Deferred Taxes Liabilities | $2,419,000,000 | $2,248,000,000 | $2,686,000,000 | $3,070,000,000 |
| Current Liabilities | $28,692,000,000 | $26,390,000,000 | $28,656,000,000 | $30,208,000,000 |
| Other Current Liabilities | $424,000,000 | $105,000,000 | $186,000,000 | $2,996,000,000 |
| Current Deferred Liabilities | $127,000,000 | $98,000,000 | $123,000,000 | $123,000,000 |
| Payables And Accrued Expenses | $9,845,000,000 | $10,141,000,000 | $11,200,000,000 | $11,143,000,000 |
| Interest Payable | $169,000,000 | $116,000,000 | $116,000,000 | $127,000,000 |
| Payables | $7,676,000,000 | $8,155,000,000 | $9,258,000,000 | $9,175,000,000 |
| Other Payable | $879,000,000 | $820,000,000 | $743,000,000 | $588,000,000 |
| Total Tax Payable | $2,225,000,000 | $2,409,000,000 | $3,369,000,000 | $3,034,000,000 |
| Income Tax Payable | $1,599,000,000 | $1,893,000,000 | $2,533,000,000 | $2,415,000,000 |
| Accounts Payable | $4,572,000,000 | $4,926,000,000 | $5,146,000,000 | $5,553,000,000 |
| Equity | ||||
| Common Stock Equity | $44,046,000,000 | $46,667,000,000 | $59,342,000,000 | $67,655,000,000 |
| Total Equity Gross Minority Interest | $44,126,000,000 | $46,750,000,000 | $59,423,000,000 | $67,822,000,000 |
| Stockholders Equity | $44,046,000,000 | $46,667,000,000 | $59,342,000,000 | $67,655,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,255,000,000 | $-3,766,000,000 | $-4,996,000,000 | $-4,187,000,000 |
| Other Equity Adjustments | $-3,255,000,000 | $-3,766,000,000 | $-4,996,000,000 | $-4,187,000,000 |
| Retained Earnings | $46,561,000,000 | $49,649,000,000 | $63,540,000,000 | $70,989,000,000 |
| Long Term Equity Investment | $119,000,000 | $205,000,000 | $143,000,000 | $205,000,000 |
| Other | ||||
| Treasury Shares Number | $214,841,249 | $233,443,766 | $284,112,195 | $199,500,000 |
| Ordinary Shares Number | $1,975,089,248 | $2,044,033,986 | $2,119,609,057 | $2,234,939,948 |
| Share Issued | $2,189,930,497 | $2,277,477,752 | $2,403,721,252 | $2,434,439,948 |
| Tangible Book Value | $-7,625,000,000 | $-3,553,000,000 | $-1,603,000,000 | $3,878,000,000 |
| Invested Capital | $73,501,000,000 | $71,187,000,000 | $85,462,000,000 | $96,784,000,000 |
| Working Capital | $1,012,000,000 | $4,091,000,000 | $8,254,000,000 | $15,510,000,000 |
| Capital Lease Obligations | $1,803,000,000 | $1,828,000,000 | $1,789,000,000 | $1,896,000,000 |
| Total Capitalization | $65,412,000,000 | $65,103,000,000 | $79,586,000,000 | $90,557,000,000 |
| Minority Interest | $80,000,000 | $83,000,000 | $81,000,000 | $167,000,000 |
| Treasury Stock | $53,000,000 | $41,000,000 | $92,000,000 | $48,000,000 |
| Capital Stock | $793,000,000 | $825,000,000 | $890,000,000 | $901,000,000 |
| Common Stock | $793,000,000 | $825,000,000 | $890,000,000 | $901,000,000 |
| Employee Benefits | $2,473,000,000 | $2,730,000,000 | $2,639,000,000 | $3,789,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $1,882,000,000 | $2,184,000,000 | $2,085,000,000 | $3,127,000,000 |
| Long Term Capital Lease Obligation | $1,568,000,000 | $1,598,000,000 | $1,538,000,000 | $1,621,000,000 |
| Long Term Provisions | $561,000,000 | $600,000,000 | $689,000,000 | $908,000,000 |
| Current Deferred Revenue | $127,000,000 | $98,000,000 | $123,000,000 | $123,000,000 |
| Current Capital Lease Obligation | $235,000,000 | $230,000,000 | $251,000,000 | $275,000,000 |
| Line Of Credit | $642,000,000 | $624,000,000 | $863,000,000 | $899,000,000 |
| Commercial Paper | $4,091,000,000 | $3,269,000,000 | $2,772,000,000 | $893,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,443,000,000 | $2,652,000,000 | $2,556,000,000 | $2,513,000,000 |
| Current Provisions | $7,529,000,000 | $7,080,000,000 | $8,464,000,000 | $6,931,000,000 |
| Current Accrued Expenses | $2,169,000,000 | $1,986,000,000 | $1,942,000,000 | $1,968,000,000 |
| Defined Pension Benefit | $2,604,000,000 | $545,000,000 | $491,000,000 | $1,415,000,000 |
| Investments And Advances | $1,128,000,000 | $1,827,000,000 | $1,606,000,000 | $2,268,000,000 |
| Other Investments | $210,000,000 | $190,000,000 | $281,000,000 | $366,000,000 |
| Held To Maturity Securities | $53,000,000 | $29,000,000 | $37,000,000 | $34,000,000 |
| Available For Sale Securities | $491,000,000 | $1,115,000,000 | $865,000,000 | $1,229,000,000 |
| Investmentsin Associatesat Cost | $119,000,000 | $205,000,000 | $143,000,000 | $205,000,000 |
| Goodwill | $24,756,000,000 | $23,341,000,000 | $29,301,000,000 | $29,595,000,000 |
| Net PPE | $10,873,000,000 | $10,924,000,000 | $12,195,000,000 | $13,106,000,000 |
| Accumulated Depreciation | $-11,100,000,000 | $-11,879,000,000 | $-14,109,000,000 | $-15,602,000,000 |
| Gross PPE | $21,973,000,000 | $22,803,000,000 | $26,304,000,000 | $28,708,000,000 |
| Construction In Progress | $1,610,000,000 | $1,213,000,000 | $1,184,000,000 | $1,508,000,000 |
| Other Properties | $58,000,000 | $66,000,000 | $64,000,000 | $37,000,000 |
| Machinery Furniture Equipment | $9,179,000,000 | $9,742,000,000 | $11,959,000,000 | $13,464,000,000 |
| Buildings And Improvements | $10,278,000,000 | $10,896,000,000 | $12,141,000,000 | $12,685,000,000 |
| Land And Improvements | $848,000,000 | $886,000,000 | $956,000,000 | $1,014,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,432,000,000 | $1,448,000,000 | $2,568,000,000 | $2,636,000,000 |
| Work In Process | $3,448,000,000 | $3,502,000,000 | $3,673,000,000 | $3,160,000,000 |
| Raw Materials | $843,000,000 | $963,000,000 | $934,000,000 | $870,000,000 |
| Other Short Term Investments | $1,892,000,000 | $569,000,000 | $11,098,000,000 | $15,706,000,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $13,805,000,000 | $11,705,000,000 | $11,997,000,000 | $12,515,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $17,619,000,000 | $14,458,000,000 | $14,236,000,000 | $15,071,000,000 |
| Cash Flow From Continuing Operating Activities | $17,619,000,000 | $14,220,000,000 | $13,039,000,000 | $13,365,000,000 |
| Operating Gains Losses | $-36,000,000 | $-167,000,000 | $-297,000,000 | $-15,983,000,000 |
| Cash From Discontinued Operating Activities | - | $238,000,000 | $1,197,000,000 | $1,706,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,814,000,000 | $-2,753,000,000 | $-2,239,000,000 | $-2,556,000,000 |
| Investing Cash Flow | $-7,513,000,000 | $5,596,000,000 | $1,468,000,000 | $4,208,000,000 |
| Cash Flow From Continuing Investing Activities | $-7,513,000,000 | $6,719,000,000 | $1,904,000,000 | $4,897,000,000 |
| Net Other Investing Changes | $3,000,000 | - | $-1,000,000 | $-55,000,000 |
| Cash From Discontinued Investing Activities | - | $-1,123,000,000 | $-436,000,000 | $-689,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-8,331,000,000 | $-8,719,000,000 | $-10,652,000,000 | $-3,057,000,000 |
| Financing Cash Flow | $-11,742,000,000 | $-14,278,000,000 | $-20,562,000,000 | $-16,264,000,000 |
| Cash Flow From Continuing Financing Activities | $-11,742,000,000 | $-17,564,000,000 | $-20,681,000,000 | $-16,290,000,000 |
| Net Other Financing Charges | $-207,000,000 | $192,000,000 | $-38,000,000 | $69,000,000 |
| Cash Dividends Paid | $-7,624,000,000 | $-7,255,000,000 | $-7,506,000,000 | $-7,368,000,000 |
| Common Stock Dividend Paid | $-7,624,000,000 | $-7,255,000,000 | $-7,506,000,000 | $-7,368,000,000 |
| Net Common Stock Issuance | $-8,331,000,000 | $-8,719,000,000 | $-10,652,000,000 | $-3,057,000,000 |
| Dividend Received Cfo | $1,000,000 | $2,000,000 | $1,000,000 | $523,000,000 |
| Cash From Discontinued Financing Activities | - | $3,286,000,000 | $119,000,000 | $26,000,000 |
| Other | ||||
| Repayment Of Debt | $-2,711,000,000 | $-2,481,000,000 | $-2,837,000,000 | $-5,987,000,000 |
| Issuance Of Debt | $7,101,000,000 | $546,000,000 | $252,000,000 | $16,000,000 |
| End Cash Position | $11,459,000,000 | $13,393,000,000 | $7,517,000,000 | $12,407,000,000 |
| Beginning Cash Position | $13,393,000,000 | $7,517,000,000 | $12,407,000,000 | $9,658,000,000 |
| Effect Of Exchange Rate Changes | $-298,000,000 | $100,000,000 | $-32,000,000 | $-266,000,000 |
| Changes In Cash | $-1,636,000,000 | $5,776,000,000 | $-4,858,000,000 | $3,015,000,000 |
| Proceeds From Stock Option Exercised | $30,000,000 | $153,000,000 | $100,000,000 | $53,000,000 |
| Common Stock Payments | $-8,331,000,000 | $-8,719,000,000 | $-10,652,000,000 | $-3,057,000,000 |
| Net Issuance Payments Of Debt | $4,390,000,000 | $-1,935,000,000 | $-2,585,000,000 | $-5,987,000,000 |
| Net Short Term Debt Issuance | $-1,491,000,000 | $-1,677,000,000 | $-2,323,000,000 | $-5,709,000,000 |
| Short Term Debt Payments | $-2,449,000,000 | $-2,223,000,000 | $-2,575,000,000 | $-5,709,000,000 |
| Short Term Debt Issuance | $958,000,000 | $546,000,000 | $252,000,000 | - |
| Net Long Term Debt Issuance | $5,881,000,000 | $-258,000,000 | $-262,000,000 | $-278,000,000 |
| Long Term Debt Payments | $-262,000,000 | $-258,000,000 | $-262,000,000 | $-278,000,000 |
| Long Term Debt Issuance | $6,143,000,000 | - | $16,000,000 | $16,000,000 |
| Net Investment Purchase And Sale | $53,000,000 | $10,849,000,000 | $4,680,000,000 | $-13,853,000,000 |
| Sale Of Investment | $3,701,000,000 | $11,596,000,000 | $39,490,000,000 | $2,738,000,000 |
| Purchase Of Investment | $-3,648,000,000 | $-747,000,000 | $-34,810,000,000 | $-16,591,000,000 |
| Net Business Purchase And Sale | $-3,921,000,000 | $-3,569,000,000 | $-864,000,000 | $20,464,000,000 |
| Net Intangibles Purchase And Sale | $-2,368,000,000 | $262,000,000 | $-1,153,000,000 | $-804,000,000 |
| Sale Of Intangibles | $80,000,000 | $1,955,000,000 | $170,000,000 | $686,000,000 |
| Purchase Of Intangibles | $-2,448,000,000 | $-1,693,000,000 | $-1,323,000,000 | $-1,490,000,000 |
| Net PPE Purchase And Sale | $-1,280,000,000 | $-823,000,000 | $-758,000,000 | $-855,000,000 |
| Sale Of PPE | $86,000,000 | $237,000,000 | $158,000,000 | $211,000,000 |
| Purchase Of PPE | $-1,366,000,000 | $-1,060,000,000 | $-916,000,000 | $-1,066,000,000 |
| Taxes Refund Paid | $-2,258,000,000 | $-2,787,000,000 | $-1,702,000,000 | $-1,856,000,000 |
| Interest Received Cfo | $489,000,000 | $645,000,000 | $252,000,000 | $11,000,000 |
| Interest Paid Cfo | $-855,000,000 | $-751,000,000 | $-667,000,000 | $-643,000,000 |
| Change In Working Capital | $-706,000,000 | $-369,000,000 | $-796,000,000 | $-73,000,000 |
| Change In Other Current Liabilities | $1,057,000,000 | $1,327,000,000 | $426,000,000 | $671,000,000 |
| Change In Other Current Assets | $-502,000,000 | $-125,000,000 | $-84,000,000 | $-179,000,000 |
| Change In Payables And Accrued Expense | $-105,000,000 | $479,000,000 | $-181,000,000 | $-111,000,000 |
| Change In Payable | $-105,000,000 | $479,000,000 | $-181,000,000 | $-111,000,000 |
| Change In Account Payable | $-105,000,000 | $479,000,000 | $-181,000,000 | $-111,000,000 |
| Change In Inventory | $-225,000,000 | $-546,000,000 | $-560,000,000 | $-102,000,000 |
| Change In Receivables | $-931,000,000 | $-1,504,000,000 | $-397,000,000 | $-352,000,000 |
| Changes In Account Receivables | $-931,000,000 | $-1,504,000,000 | $-397,000,000 | $-352,000,000 |
| Other Non Cash Items | $-510,000,000 | $-785,000,000 | $-3,000,000 | $-209,000,000 |
| Stock Based Compensation | $1,044,000,000 | $865,000,000 | $791,000,000 | $700,000,000 |
| Provisionand Write Offof Assets | $696,000,000 | $61,000,000 | $1,318,000,000 | $806,000,000 |
| Amortization Of Securities | $45,000,000 | $106,000,000 | $260,000,000 | $-38,000,000 |
| Deferred Tax | $1,701,000,000 | $551,000,000 | $1,128,000,000 | $1,625,000,000 |
| Deferred Income Tax | $1,701,000,000 | $551,000,000 | $1,128,000,000 | $1,625,000,000 |
| Depreciation Amortization Depletion | $6,069,000,000 | $8,277,000,000 | $6,705,000,000 | $5,597,000,000 |
| Depreciation And Amortization | $6,069,000,000 | $8,277,000,000 | $6,705,000,000 | $5,597,000,000 |
| Amortization Cash Flow | $4,881,000,000 | $7,008,000,000 | $5,061,000,000 | $4,041,000,000 |
| Amortization Of Intangibles | $4,881,000,000 | $7,008,000,000 | $5,061,000,000 | $4,041,000,000 |
| Depreciation | $1,188,000,000 | $1,269,000,000 | $1,644,000,000 | $1,556,000,000 |
| Earnings Losses From Equity Investments | $38,000,000 | $13,000,000 | $11,000,000 | $-15,337,000,000 |
| Gain Loss On Sale Of PPE | $-74,000,000 | $-180,000,000 | $-308,000,000 | $-646,000,000 |
| Net Income From Continuing Operations | $11,939,000,000 | $8,572,000,000 | $6,049,000,000 | $22,905,000,000 |
Fetched: 2026-02-02